|
|
| Line 5: |
Line 5: |
|
| |
|
| ==Overview== | | ==Overview== |
|
| |
| ==Historical Perspective==
| |
|
| |
| ===Discovery===
| |
| *In 1871, Bilroth, a Prussian-born Austrian surgeon, was the first to described a case of Non- Hodgkin lymphoma, and coined the term malignant lymphoma.
| |
| *In 1864, Virchow , a German physician , described lymph node enlargement not related to leukemia as lymphosarcoma a subdivision of aleukimic type of lukemias.
| |
| *In 1865, Cohnheim, a German-Jewish physician , used the term pseudolukemia to describe all common lymphadenopathy and splenomegaly. <ref {{cite book | last = Pollock | first = Raphael | title = Advanced therapy in surgical oncology | publisher = BC Decker Inc | location = Hamilton, Ontario Lewiston, NY | year = 2008 | isbn = 9781550091267 }}</ref>
| |
| *In 1958, [[Denis Parsons Burkitt]], an Irish [[surgeon]], first discovered Burkitt's lymphoma while working in Africa.<ref name="pmid13628987">{{cite journal |author=Burkitt D |title=A sarcoma involving the jaws in African children |journal=The British journal of surgery |volume=46 |issue=197 |pages=218–23 |year=1958 |pmid=13628987|doi=10.1002/bjs.18004619704}}</ref>
| |
| *In 1925, Follicular lymphoma was described by Brill and Symmers independently.<ref{{cite journal |vauthors=van Besien K, Schouten H |title=Follicular lymphoma: a historical overview |journal=Leuk. Lymphoma |volume=48 |issue=2 |pages=232–43 |date=February 2007 |pmid=17325883 |doi=10.1080/10428190601059746 |url=}}</ref>
| |
| *In 1956, Henry Rappaport and his colleagues proposed the Rappaport classification, based on cellular morphology, this became the first widely accepted classification of non- Hodgkin lymphomas.
| |
| *In 1966, Armed Forces Institute of Pathology (AFIP) modified the the Rappaport classification in the"Tumors of the Hematopoietic System".
| |
| *In 1982, National Cancer Institute introduced the Working Formulation, an amalgamation translating all previous classifications, which defined three grades of non-Hodgkin lymphoma.<ref name="BennettFarrer-Brown1974">{{cite journal|last1=Bennett|first1=MichaelH.|last2=Farrer-Brown|first2=Geoffrey|last3=Henry|first3=Kristin|last4=Jelliffe|first4=A.M.|last5=Gerard-Marchant|first5=R.|last6=Hamlin|first6=Iris|last7=Lennert|first7=K.|last8=Rilke|first8=F.|last9=Stansfeld|first9=A.G.|last10=Van Unnik|first10=J.A.M.|title=CLASSIFICATION OF NON-HODGKIN'S LYMPHOMAS|journal=The Lancet|volume=304|issue=7877|year=1974|pages=405–408|issn=01406736|doi=10.1016/S0140-6736(74)91786-3}}</ref>
| |
| *In 1992, Banks first coined the term [[Mantle Cell Lymphoma|mantle cell lymphoma]] (MCL).<ref name="pmid1530105">{{cite journal| author=Banks PM, Chan J, Cleary ML, Delsol G, De Wolf-Peeters C, Gatter K et al.| title=Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. | journal=Am J Surg Pathol | year= 1992 | volume= 16 | issue= 7 | pages= 637-40 | pmid=1530105 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1530105 }} </ref>
| |
| *In 1994, the Revised European-American Classification of Lymphoid Neoplasms (REAL) classified non Hodgkin's lymphoma, based on immunologic, genetic and clinical characteristics of the disorders in addition to histopathologic characteristics of the tumor cells.
| |
|
| |
|
| ==Landmark Events in the Development of Treatment Strategies== | | ==Landmark Events in the Development of Treatment Strategies== |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Landmark Events in the Development of Treatment Strategies
- In 1997, FDA approved rituximab, to treat patients with B-cell non-Hodgkin lymphoma that did not responds to other treatments.[1]
Impact on Cultural History
Famous Cases
The following are a few famous cases of disease name:
References
- ↑ Grillo-López AJ, White CA, Dallaire BK, Varns CL, Shen CD, Wei A, Leonard JE, McClure A, Weaver R, Cairelli S, Rosenberg J (July 2000). "Rituximab: the first monoclonal antibody approved for the treatment of lymphoma". Curr Pharm Biotechnol. 1 (1): 1–9. PMID 11467356.
Template:WH
Template:WS